z-logo
Premium
Do systemic antibiotics increase the survival of a full thickness graft on the nose?
Author(s) -
Kuijpers DIM,
Smeets NWJ,
Lapière K,
Thissen MRTM,
Krekels GAM,
Neumann HAM
Publication year - 2006
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2006.01792.x
Subject(s) - medicine , nose , systemic antibiotics , surgery , melanoma , antibiotics , azithromycin , skin cancer , cancer , randomized controlled trial , microbiology and biotechnology , biology , cancer research
Background  Full thickness grafts on the nose do not always heal without problems. Partial or entire necrosis of the graft is likely to lead to less favourable cosmetic results and prolonged wound care. No consensus exists as to the use of systemic antibiotics to increase the success rate of survival of a full thickness skin graft on the nose after non‐melanoma skin cancer surgery. Objective  The objective of the study was to evaluate the effect of systemic antibiotics on the survival of full thickness grafts on the nose. Methods  We performed a randomized, controlled trial in which we compared azithromycin with standard treatment in 30 patients, who underwent a full thickness graft reconstruction of a surgical defect on the nose after surgery for non‐melanoma skin cancer. Percentage survival of the graft was the main outcome measure. Results  A statistically significant difference in favour of the grafts treated with azithromycin was seen ( P =  0.002). Of all the variables analysed, only smoking had a significant negative effect on the survival of the graft. Conclusions  Systemic antibiotics with an accurate bacterial spectrum should be advised in full thickness skin graft reconstruction after surgery for non‐melanoma skin cancer of the nose. Smoking should be strongly discouraged.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here